Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies

By Gibney Geoffrey T  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 7, 2013-07 ,pp. : 893-899

Informa Healthcare

Access to resources Recommend Favorite

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

By Bose Prithviraj   Simmons Gary L   Grant Steven  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 723-738

Informa Healthcare

Access to resources Recommend Favorite

Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas

By Lo Roger S  

Pharmacogenomics, Vol. 13, Iss. 2, 2012-01 ,pp. : 125-128

Future Medicine

Access to resources Recommend Favorite

Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies

By Sharma Anant   Shah Sachin R.   Illum Henrik   Dowell Jonathan  

Drugs, Vol. 72, Iss. 17, 2012-12 ,pp. : 2207-2222

Adis International

Access to resources Recommend Favorite

Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies

By Jain Nitin   Odenike Olatoyosi  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 3073-3084

Informa Healthcare

Access to resources Recommend Favorite